Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $428 | In Stock | |
5 mg | $1,370 | In Stock | |
10 mg | $1,850 | In Stock | |
25 mg | $2,730 | In Stock | |
50 mg | $3,680 | In Stock | |
100 mg | $4,900 | In Stock |
Description | Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma. |
In vitro | In an E/T ratio-dependent manner, tafasitamab (XmAb5574) induced cytotoxicity to Mino and Jeko (MCL) cell lines. It also increased antibody-dependent cellular phagocytosis (ADCP) and antiproliferative activity. Additionally, tafasitamab (XmAb5574) can enhance the anti-proliferative activity induced by caspase-mediated apoptosis[1][2]. |
In vivo | In a xenograft tumor model of disseminated BL mice, tafasitamab (2.5 μg/kg, once on day 1) inhibited lymphoma growth[1]. |
Alias | XmAb5574, Tafasitamab-cxix, MOR00208 |
Molecular Weight | 147.41 kDa |
Cas No. | 1422527-84-1 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.